Core Insights - Elutia Inc. announced the successful preclinical data publication for EluPro, the first antibiotic-eluting biologic envelope cleared by the FDA, demonstrating its effectiveness in eradicating bacteria associated with cardiovascular implantable electronic devices (CIEDs) [1][4] - EluPro has received FDA clearance for use with CIEDs and additional devices, with the first patient implant completed in September 2024, and a commercial launch planned for January 2025 [2][4] Group 1: Product Efficacy - EluPro significantly reduced bacterial colonization in an established rabbit model, achieving complete eradication of methicillin-resistant staphylococcus aureus (MRSA) and other strains, with no signs of infection in animals receiving EluPro [3] - The product demonstrated sustained local antibiotic release for over a week with minimal systemic exposure, highlighting the advantages of local drug delivery [3] Group 2: Clinical and Regulatory Milestones - The FDA clearance for EluPro includes its use with neuromodulators and neurostimulators for various medical conditions, indicating a broad application potential [2] - The first human implant of EluPro marks a significant milestone for the company, paving the way for its upcoming commercial launch [4] Group 3: Expert Endorsements - Experts, including Dr. M. Rizwan Sohail, emphasize EluPro's potential to improve implant stability, reduce device migration, and minimize scarring and fibrosis, which could facilitate easier reoperations [3] - Michelle LeRoux Williams, Elutia's Chief Scientific Officer, reinforced the product's role in enhancing infection control for CIED procedures, marking a significant advancement in implantable device protection [4]

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible. On September 6, 2023, as part of a strategic shift toward drug-eluting biologics, the company rebranded as Elutia Inc. and established the mission of "Humanizing Medicine so Patients can Thrive without C ...

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac ...

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: H.C. Wainwright 26th Annual Global Investment Conference Format: Presentation and 1x1 Meetings Presentation Date and Time (On-demand beginning): Monday, September 9, 2024, 7: ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |--------------------------------------------------|---------------------------------------------------------------------------------------------- ...

2nd Quarter 2024 Financial Results Call C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer August 7, 2024 Forward-Looking Statements This presentation of Elutia Inc. ("Elutia," "we," "us," "our" or the "Company") (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical facts, including but not limited to statements regarding the market potential ...

Elutia Inc. (NASDAQ:ELUT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners, IR Randy Mills - President and CEO Matt Ferguson - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Second Quarter 2024 Financial Results Call. At this time, all participants are in listen-only mode. The question-and-answer session will follow the fo ...

Exhibit 99.1 Elutia Announces Second Quarter 2024 Results Launch Production of EluPro Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., August 7, 2024 — Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the second quarter ended June 30, 2024. Business Highlights: · Received FDA clearance for EluPro, the first antibiotic-eluting BioEnvelope for protecti ...

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Ope ...

Company Overview - Elutia Inc. is a pioneer in drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients [3] - The company's mission is to humanize medicine, allowing patients to thrive without compromise, particularly in the context of a growing population in need of implantable technologies [3] Upcoming Presentation - Dr. Randy Mills, President and CEO of Elutia, will present at the Emerging Growth Conference on July 18, 2024, at 12:35 p.m. ET [1] - Following the presentation, Elutia management will engage in one-on-one investor meetings, with institutional investors encouraged to schedule meetings via email [2] Conference Details - The Emerging Growth Conference serves as a platform for public companies to present new products, services, and major announcements to the investment community efficiently [4] - The conference targets a wide range of growth sectors and attracts a diverse audience, including individual and institutional investors, investment advisors, and analysts [5]